癌症研究
CD8型
兴奋剂
医学
转录组
嵌合抗原受体
淋巴瘤
细胞
T细胞
肿瘤进展
下调和上调
免疫系统
细胞毒性T细胞
免疫学
受体
细胞生长
细胞培养
体内
生物
敌手
肿瘤微环境
免疫疗法
细胞周期
调节性T细胞
白细胞介素2
内科学
药理学
受体拮抗剂
临床试验
白细胞介素1受体拮抗剂
炎症
细胞周期进展
作者
Kotaro Arita,Enyu Dai,Xubin Li,Irtiza N. Sheikh,Patrick Kevin Reville,Jared M. Henderson,Ashley Lauren Wilson,C.Q. Dillard-Ilboudo,Kevin Bowman,Haopeng Yang,Fuliang Chu,Robert Andrew Harkins,Nathan Pate,Katie Malley,Dinesh S. Bangari,Estela Rojas,Jason R. Westin,Sairah Ahmed,Sattva Swarup Neelapu,Francisco Vega
出处
期刊:Blood
[Elsevier BV]
日期:2026-10-23
标识
DOI:10.1182/blood.2026033885
摘要
Chimeric antigen receptor T-cell (CART19) therapy represents a breakthrough for relapsed or refractory large B-cell lymphoma (rrLBCL). However, suboptimal CART19 activity can lead to therapeutic failure and dismal outcomes. Through single cell RNA-sequencing of tumors at the time of progression from CART19, we show that a subset of tumor contain clonally expanded and proliferating populations of CART19 cells that acquire transcriptional features of dysfunction, suggestive of ongoing tumor cell engagement and chronic stimulation. Using an in vitro system to model this process, we show that iterative rechallenge of CART19 cells with target cells drives failure of tumor control associated with acquired transcriptomic features of T-cell dysfunction and reduced IL2 signaling. Pegenzileukin, a non-alpha IL2-receptor agonist, prevented CART19 dysfunction, improving T-cell expansion and tumor control in vitro. To test this concept in vivo, we developed a cell line model from a post-CART19 progression tumor that reproduces the response and failure kinetics observed in the originating patient. In vivo CART19 alone led to transient response followed by progression and secondary central nervous system relapse in this model, while the addition of pegenzileukin to CART19 led to the complete eradication of tumors. This provides mechanism-informed pre-clinical rationale for the use of non-alpha IL2 receptor agonists in combating T-cell exhaustion, a critical mechanism of CART19 failure.
科研通智能强力驱动
Strongly Powered by AbleSci AI